Investigation opened into iRhythm Technologies following missed earnings targets
Investors represented by SueWallSt are reviewing potential securities law violations by iRhythm Technologies after revenue fell short of consensus and key product timelines slipped.
The firm SueWallSt has initiated an investigation into iRhythm Technologies (IRTC) regarding potential violations of securities laws. The probe follows a period of financial underperformance, characterized by revenue figures that failed to meet Wall Street expectations.
Significant operational hurdles have also emerged, with flat sales reported for the company’s Zio AT product line. Furthermore, management confirmed that the FDA submission process for the Zio MCT device has been delayed until 2027, adding further pressure on the company’s growth trajectory.
The investigation aims to determine if the company provided inaccurate or misleading information to shareholders regarding its business health. Investors who suffered financial losses are currently reviewing the potential for legal recourse to recover capital.